Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | LAP3 | P28838 | 3/20 | 0.38 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 3/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169057 | 0.89 | CSNK1E (0.43) | CSNK1ECCR1F2LAP3SPPL2A | |
| SCHEMBL6168937 | 0.87 | CCR1 (0.45) | CSNK1ECCR1SLC1A1REN | |
| SCHEMBL2675073 | 0.81 | CCR1 (0.57) | CSNK1ECCR1LAP3ANPEPRNPEP | |
| SCHEMBL2675795 | 0.79 | CCR1 (0.50) | CSNK1ECCR1LAP3ANPEPRNPEP | |
| SCHEMBL4066887 | 0.77 | CCR1 (0.52) | CSNK1ECCR1LAP3ANPEPRNPEP | |
| SCHEMBL7177687 | 0.77 | CSNK1E (0.41) | CSNK1ECCR1F2LAP3SPPL2A | |
| SCHEMBL6164192 | 0.74 | SPPL2A (0.47) | CSNK1EF2LAP3SPPL2AANPEP | |
| SCHEMBL4066102 | 0.73 | CCR1 (0.45) | CSNK1ECCR1LAP3ANPEPRNPEP | |
| SCHEMBL6167994 | 0.71 | CSNK1E (0.40) | CSNK1ECCR1LAP3ANPEPRNPEP | |
| SCHEMBL6167499 | 0.71 | CCR1 (0.57) | CSNK1ECCR1LAP3ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498417-A1 | Heterocyclic amide derivatives | Pfizer Products Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | claimed |
| EP-1252154-A1 | HETEROCYCLIC AMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | claimed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | claimed |
| WO-2001057023-A1 | HETEROCYCLIC AMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
| EP-1498417-A1 | Heterocyclic amide derivatives | Pfizer Products Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| EP-1252154-A1 | HETEROCYCLIC AMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2001057023-A1 | HETEROCYCLIC AMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132810-A1 | Novel heterocyclic amide derivatives | ARG1, IL4, ARG2 | CSNK1E 1897/4885CCR1 32/4885F2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.